Pseudotumour after arteriovenous malformation embolisation

The association between venous outflow obstruction and the development of pseudotumour syndrome is well known, although the mechanism by which the rise in CSF pressure is brought about is less certain. Although there is much evidence that the manifestations are a result of a disturbance of CSF dynamics, previous reports have focused solely on a disturbance to absorption. We present a case in which it is proposed that alterations in CSF formation, and to a lesser extent absorption, are responsible for the development of the syndrome.

At 2 years of age, as part of investigating a family history of abnormal growth, a female infant underwent cerebral CT. This showed an unexpected arteriovenous malformation involving the vein of Galen. Although there was no evidence of cardiac failure or hydrocephalus associated with this, assessment by angiography was advised. This, initially declined by the parents, was not undertaken until the age of 5 years when vertigo and intermittent numbness of the left arm and leg had been present for about 12 months.

Angiography showed a deep right temporal lobe arteriovenous malformation consisting of three separate fistulae supplied by the right posterior cerebral and posterior communicant arteries. These drained into a large venous varix which subsequently drained into the Galenic venous system. A cerebral blood flow study showed a steal syndrome affecting the right frontoparietal area, and a decision was made to attempt embolisation. Complete occlusion of the fistulae was achieved by transarterial platinum coil embolisation.

The patient complained of right sided headache for 24 hours after the procedure, resolving with minor analgesia. Brain CT the next day was reported as normal. A full ophthalmological review was undertaken before discharge showing normal fundi and fields.

Ten days after the embolisation the patient presented with a generalised, pounding headache, present since discharge. Examination showed mild left papilloedema, with no focal aches, present since discharge. Examination of the right frontoparietal area, and a decision was made to attempt embolisation. Complete occlusion of the fistulae was achieved by transarterial platinum coil embolisation.

It is well known that obstruction to a major portion of the cranial venous outflow can produce intracranial hypertension, presumably by impairing CSF absorption across the arachnoidal villi. In the present case it would seem that sluggish flow in the venous varix after embolisation has resulted in thrombosis, which has propagated to the vein of Galen. As all investigations seem to have the thrombus confined to this region, a region of relative paucity of arachnoidal granulations, and the major outflow tracts seem normal, it is difficult to accept that impairment of absorption is the mechanism responsible in the current case. An alternative mechanism must be considered.

It is held that one of the determinants of the rate of CSF production is the pressure gradient across the choroid plexus capillaries. Reduction in this pressure has been shown to decrease the rate of CSF formation, and it is possible that increases in the transcapillary pressure will, as in other parts of the body, result in increased transudation from the capillaries, leading to increased CSF formation. The malformation in the present case, haemodynamically important enough to result in symptoms of steal, and present since birth, may have resulted in a subnormal transcapillary gradient, and hence a possibly decreased CSF production. If this were the case, with decreased production serving to retard the normal development of absorptive capacity, then the increase in the venous pressure in the choroid plexus capillaries brought about by both the closure of the fistulae and the subsequent venous thrombosis may have resulted in a rate of CSF production greater than could be handled by the absorptive system. Resolution of the thrombus, recruitment of venous collaterals, and possibly an increase in absorptive capacity would have resulted in the resolution of the syndrome.

Dandy and Blackfan, in one of the first experiments of its type, attempted to produce hydrocephalus in dogs by ligating the vein of Galen. Their aim was to increase production, rather than impair absorption, of CSF. Their failure, a result conclusively demonstrated by Bedford, was taken to show that venous obstruction would not result in hydrocephalus. It is, however, worth noting that Bedford was able to demonstrate both the fact that dogs have extensive collaterals in the Galenic venous system, not present in humans, and that whereas Galenic venous obstruction produced little change, obstruction of the jugular veins resulted in increased CSF formation. Since these experiments little, if any, work has been done in the area of the relation between CSF formation and venous occlusion.

Although the above report is somewhat speculative, it could serve to explain the facts which at this stage of our understanding of CSF dynamics cannot be conclusively accounted for. A case of pseudotumour developing in the setting of minimal venous thrombosis, particularly in part of the venous system not thought to play a major role in the absorption of CSF, must force us to reconsider our opinions as to the relation between venous obstruction and CSF dynamics.

This research was supported by the Madeline Foundation for Neurosurgical Research.

CHRISTOPHER D KOLLAR
Madeline Foundation Laboratory, University of Sydney, Australia

IAN H JOHNSTON
Department of Neurosurgery, Royal Alexandra Hospital for Children, Sydney, Australia

Correspondence to: Correspondence to: Dr Christopher Kollar, Madeline Foundation Laboratory, Room 323, Building D06, University of Sydney, Sydney, Australia. Telephone 0061 2 9351 3359; fax 0061 2 9351 4887; kollar@surgey.usyd.edu.au

1 Symonds CP. Hydrocephalic and focal cerebral symptoms in relation to thrombophlebitis of the dural sinuses and cerebral veins. Brain 1937;48:251–50.
5 Bedford THB. The great vein of Galen and the syndrome of increased intracranial pressure. Brain 1934;57:1–24.

False negative polymerase chain reaction on cerebrospinal fluid samples in tuberculous meningitis established by culture

The polymerase chain reaction (PCR) has been reported to be of diagnostic value when performed on CSF samples in tuberculous meningitis. Examination of CSF disclosed a lymphocytic exudate. Repeated samples were sent to a British referral laboratory where CSF PCR for M tuberculosis was reported negative. Despite this, antituberculous treatment was continued for 12 months and both patients responded clinically. Several weeks after the negative PCR result, M tuberculosis was cultured on Lowenstein-Jensen slopes from CSF taken from both patients. False negative CSF PCR in tuberculous meningitis established by culture has rarely been reported. The two patients are described to emphasise the dangers of overreliance on PCR in cases of suspected tuberculous meningitis. Premature cessation of treatment would have had tragic consequences for the two patients concerned.

The first patient was a 28 year old Asian man, last in India 8 years previously. He was sent from a clinic to hospital for incision and drainage of two deep seated Staphylococcus.
examination she had mild neck stiffness. Appendicectomy and had received antituberculous therapy for 6 years during laparotomy for an ovarian cyst. She presented with a 3 month history of increasing fatigue and a raised protein concentration in the CSF. Laboratory and PCR for Mycobacterium tuberculosis grew a fully sensitive organism. Deoxynucleotidyl transferase activity in CSF showed a high opening pressure (15 cm CSF), and the X chromosome (CMTX). CMT1B is associated with another unknown chromosome, (CMT1C).

We are grateful to Dr Deborah Binzi-Gascogne of the Leeds mycobacterium laboratory, where the PCR tests were performed and who provided additional information for the manuscript.

been recognised in Dejerine-Sottas disease, peripheral neuropathy with an early onset in childhood, and a more severe phenotype than CMT1. CMT1 and Dejerine-Sottas disease are characterised by thickening of peripheral nerves, and thickening of the cauda equina, nerve roots, and ganglia have often been found. Although cranial nerves are generally spared in CMT, thickening of the acoustic or optic nerve has been reported. In some cases, thickening of cranial nerves is rare and thickening of cranial nerves has not been reported except for the acoustic or optic nerves in patients with CMT. Symptomatic variants of CMT, such as Charcot-Marie-Tooth disease. Although her facial sensation, mastication power, and hearing acuity were normal, the thickness of bilateral trigeminal nerves on MRI and prolongation of the I-III interpeak intervals in auditory brain stem response were found. The I-III interpeak interval represents the conduction time from the eighth nerve to the pontomedullary portions of the auditory pathway. Prolongation of the auditory brain stem response suggests peripheral conduction delay of the auditory nerve.

Trigeminal neuralgia with CMT has been reported. In these rare cases, trigeminal neuralgia was inherited, suggesting a partial symptom of CMT. Although some patients were surgically treated, it was not clear whether a thickened trigeminal nerve was present. Moreover, on electrophysiological studies of facial and trigeminal nerves in CMT, Kimura reported that the sensory component of the trigeminal nerve was relatively spared, despite extremely delayed conduction of the sensory response. However, the MRI study of our patient suggested that the fifth cranial nerves were subjected to the same pathological process that affects other peripheral nerves.

Our patient showed no DNA duplication on chromosome 17p11.2 and we found a novel mutation (A→C substitution in the P0 gene). This mutation was absent in the DNA from 100 controls. Therefore, we identified this mutation as pathogenic. Arg→His was located in exon 3, which codes for the extracellular domain of P0. This extracellular domain plays a part in myelin compaction by homophilic interaction and many mutations in this area have been reported. Although the phenotypic variability is related to the position and nature of the P0 mutation, patients with cranial nerve involvement are rare in CMT with a P0 mutation. Therefore, the unique thickening of trigeminal nerves and the clinical severity in this patient may be related to this novel missense mutation. A careful comparison of the clinical, electrophysiological, and histopathological data between patients with CMT should be conducted.

We are indebted to the families studied for their cooperation and support. This work was partly supported by Uehara Memorial Foundation, the Sasa- kawa Health Science Foundation, the Primary Amyloidosis Research Committee, and the Ministry of Education, Science and Culture of Japan, 19823299.

MASAMI SHIZUKA
YOSHIKO IKEDA
MITSUNORI WATANABE
KOICHI KAMOTO
MIKIO SHOJI
Department of Neurology, Gunma University School of Medicine, 3–39–22 Showa-machi, Maebashi, Gunma 371–8511, Japan

TORU UEGAMI
KIYOSHI HAYASAKA
Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan

Correspondence to: Dr Masami Shizuka, Department of Neurology, Gunma University School of Medicine, 3–39–22 Showa-machi, Maebashi, Gunma 371–8511, Japan. Telephone 0081 27 220 8068; fax 0081 27 220 8068; email mshizuka@news.sb.gunma-u.ac.jp


Intracranial extracerebral follicular lymphoma mimicking a sphenoid wing meningioma

Primary lymphoma in the brain is uncommon, accounting for only 2% of primary intracranial neoplasms. Although its incidence seems to be dramatically increasing, leukemoidal lymphomas are even rarer but have been described. However, no leptomeningeal lymphoma of the follicular type has previously been reported. We present a case of a primary meningeal follicular lymphoma which mimicked a sphenoid wing meningioma, both radiologically and intraoperatively.

A 47 year old Ghanaian woman was referred with a 3 year history of worsening bitemporal headache, followed by a 6 month history of daily right frontal headache lasting for 2–3 hours associated with mild photophobia. There were no reports of seizures, nausea, or other visual disturbances. Her medical history was 3 years of treated hypertension, sickle cell carrier trait, and a cataract extraction. The patient was obese but physical examination was otherwise normal. Neurological examination showed no papilloedema and there were no cranial nerve or long tract signs.

Brain CT showed an enhancing mass consistent with a right sided sphenoid wing meningioma...
The patient made an uneventful recovery and was referred for staging investigations and consideration of postoperative therapy. An LDH estimation was within normal limits and HIV serology was negative. Whole body CT including repeat CT of the brain did not show any evidence of lymphadenopathy or lymphomatous deposit. Bone marrow examination was declined. Postoperative adjuvant chemotherapy was discussed with the patient, however, she declined any further intervention. She has been closely reviewed in the follow up clinic and after 6 months there has been no clinical or radiological evidence of recurrent disease.

Primary intracerebral lymphomas represent about 2% of intracranial neoplasms and 2% of all lymphomas. They occur most commonly in the 6th decade of life with a female to male ratio of roughly 2:1.1 There is only one previous report of a follicular lymphoma of the cerebrospinal fluid.2 However, the complex mechanisms by which copper crosses into the CSF, and the factors determining the CSF copper concentration in humans are largely obscure. Copper can pass into and out of the CSF by various mechanisms. For example, active transport through the blood-brain barrier or the blood-CSF barrier, or passive diffusion of the free or the bound fraction (bound to albumin or coereuloplasmin) through the blood-CSF barrier. We studied the factors influencing CSF copper concentration using a stepwise multiple linear regression model. The independent variables were age, plasma coeruloplasmin, CSF/serum albumin ratio, total serum copper concentration, and calculated serum free copper concentration (based on serum coereuloplasmin and total serum copper concentration). The CSF copper concentration was calculated as a continuous type. We investigated lumbar CSF samples from 113 patients. These patients had dementia, extrapiramidal, or tremor symptoms; lumbar puncture was performed to exclude Wilson’s disease, and none of the patients had the disease. Copper was measured by flameless atomic absorption (Perkin Elmer, HGA 500, Ueberlingen, Germany). Coeruleoplasmin was determined nephelometrically (Beckman Instruments, Brea, CA, USA). The age of the patients was 50.0 (SD15.5) years; 50 were women and 63 were men. Mean serum coeruleoplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coeruloplasmin concentrations were 394.3 (SD 77.1) mg/l. Mean serum copper concentrations were 1194 (SD 335) µg/l. Mean serum coercion...
stepwise linear regression model \( F \) to enter 4.0, \( F \) to remove: 3.9(96), significant positive predictive power of the CSF copper concentration were found to be AR(p=0.0001) and serum coeuroplasmin (p=0.0057). The other independent variables mentioned above showed no statistically significant relation with CSF copper concentration. The figure shows the simple linear regression between CSF/serum albumin ratio and CSF copper concentration (on logarithmic axes): \( R^2=0.46, p=0.0001 \). The formula for the CSF copper concentration, derived from the multiple linear regression model, is: copper CSF (µg/l)=5.32 

 Albumin ratio (CSF/serum, log)

Correlation of blood-CSF barrier (albumin ratio, (AR)) with total CSF copper concentration (on logarithmic axes), \( R^2=0.46, p=0.0001 \); 95% confidence bands for the true mean of the total CSF copper concentration are shown.

Solitary intracranial myofibroma in a child

A rare case of solitary interhemispheric myofibroma with excellent outcome in a 20 month old boy is described. The clinicopathological features of this unusual condition are reviewed with emphasis on the CNS manifestations.

A case of congenital fibrosarcoma was first diagnosed by William and Schrum and was subsequently renamed congenital generalised fibromatosis by Stout in 1954 as a distinct form of juvenile fibromatosis characterised by tumour-like nodules involving the skin, soft tissues, bones, and viscera. Based on the ultrastructural and immunohistochemical features of the cell of origin and the occurrence of this condition in infants, as well as congenitally, it was renamed infantile myofibromatosis by Stout in 1954. This disorder is considered to represent a hamartomatous myofibroblastic proliferation, although laboratory evidence suggests that it may arise secondary to oestrogen stimulation in utero. Infantile myofibromatosis represents the most common fibrous tumour of infancy and may present with solitary or multilobar involvement. When visceral involvement is present a multilobar form is termed “generalised”. Cases with familial incidence, spontaneous regression, and fatal outcome have all been described. Poor outcome has generally been associated with extensive visceral involvement and relates either to mass effect with compression of vital organs and structures, or to pulmonary involvement, when submucosal or subcutaneous cellular proliferation results in vascular or bronchial obliteration.

Central nervous system involvement is exceptionally rare and has been reported as a finding in the multilobar type of myofibromatosis. We describe a solitary interhemispheric myofibroma which presented as an intracranial mass in a 20 month old child. To our knowledge, only one other case of solitary intracranial myofibromatosis has been reported.

A 20 month old Irish boy, the only son of healthy, unrelated parents, was admitted for investigation of a large head. He had one previous hospital admission at the age of 6 weeks for a respiratory tract infection. The patient’s head circumference was noted at that time as being a skull circumference of 43 cm. At 6 months there was no hypotonia, neurological examination was normal, and the head circumference was 49 cm. The patient’s head circumference was 61 cm and he stated that all of his family had “big heads”. By 20 months, the patient’s head circumference measured 55.6 cm and was diverging from the 97th centile. Brain CT showed a well circumscribed, contrast enhancing mass in the midline and left frontal lobe, with surrounding oedema. There was evidence of left sided hydrocephalus due to displacement of the right foramen of Munro by tumour. The radiological differential diagnosis included a primary meningeal tumour, glioma, and leukaemic deposit. The patient underwent a left frontal craniotomy and a firm, rounded mass was removed from the vessel, it was assessed and only around 0.09% by passive diffusion bound to coeuroplasmin, and only around 0.09% by passive diffusion bound to albumin. In the case of a markedly raised CSF/serum albumin ratio of 20±10, this would mean that 60.6% of the measured CSF copper originated from the blood (bound to coeuroplasmin). A variable fraction of the CSF copper concentration, depending on the degree of damage to the blood-CSF barrier, therefore crosses from the blood into the CSF and can be measured there. Our formula would therefore predict, in patients with Wilson’s disease with intact blood-CSF barrier (assuming a CSF/serum albumin ratio of 6.5±10), that the CSF copper concentration is actually reduced by 27.4%, when the serum coeuroplasmin concentration falls from its normal value of 394 mg/l to 66 mg/l. In consequence, CSF copper in patients with Wilson’s disease is evidently substantially free, implying that a larger fraction than previously assumed of the raised CSF copper in patients with untreated Wilson’s disease originates from the brain, the fraction entering the CSF by passive diffusion (bound to coeuroplasmin) tends towards zero. It can be concluded from this that, when the aim of therapy is considered in terms of the total CSF copper concentration, a region around 30% lower than the upper limit of the normal range should be aimed for. This is supported by the clinical finding that patients report feeling better when the CSF copper concentration is below this value. This analysis also shows that the raised copper concentration in the CSF can only originate from the brain. In particular, it is not associated with free serum copper, but evidently only via storage in the brain. The investigation here also shows that, after determining the CSF copper concentration, the coeuroplasmin-bound fraction originating from the plasma should be subtracted accordingly from the result we have given, or better, all measured copper concentrations in the CSF should be adjusted using the CSF/serum albumin ratio and serum coeuroplasmin concentration. A statistical relation with a low correlation (\( p=0.05 \)) between CSF protein content and CSF copper was already shown in various neurological diseases; our study shows a much higher significance and, in addition, the effect of serum coeuroplasmin (therefore of bound serum copper). Furthermore, we have been able to determine specifically the contribution of CSF copper which enters the CSF across the blood-CSF barrier.

HANS JOERGSTUERENBURG  
MATTHIAS OECHSNER  
SVEN SCHROEDER  
KLAUS KUNZE  
Neurological Department, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany  
Correspondence to: Dr Hans Joerg Stuermen, Neurological Department, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany  
Telephone 0049 40 4717 4832; fax0049 40 4717 5086.


myoglobin. Ultrastructural examination showed elongated cells with surrounding collagen fibrils, some showing intracytoplasmic myofilaments.

Solitary lesions of infantile myofibromatosis are more common than multiple lesions, with twice as many males as females being affected, and generally involve the skin and soft tissues, especially of the head and neck.  

Solitary lesions are less commonly found in viscera or bones.  

Involvement of the CNS is exceedingly rare and only one other case of a solitary mass is reported along with few cases of CNS involvement in the generalised form of infantile myofibromatosis.  

The prenatal diagnosis is best for cases with solitary masses and less favourable for multicentric cases, particularly where visceral lesions are present, in which morbidity and mortality derive predominantly from pulmonary involvement or mass effect.

The differential diagnosis for this lesion included meningioma, schwannoma, and haemangiopericytoma. Regionally, the histology was reminiscent of the rare microscopic variant of meningioma. Meningiomas are extremely rare in this age group, this lesion and muscle actions potentials (1.18 mV) and slow muscle contraction (0.1 mV) in the peroneal nerve. There were also markedly decreased amplitudes of the sensory nerve action potentials (3.11 mV) and sural (0.98 mV) nerves. These findings and the clinical features confirmed the diagnosis of sensory dominant, axonal polyneuropathy. The patient was diagnosed as having VTEC infection, because of a typical history of an acute haemorrhagic colitis, the cultured growth of enterohaemorrhagic E coli O157:H7, and the detection of verotoxin in her stool. She had haemolytic-uraemic syndrome (haemolytic anaemia, thrombocytopenia, and uraemia, following diarrhoea), which is the main complication of VTEC infection. Experimentally, vero cells, an immortalised primate kidney cell line, can be lysed by increasing doses of verotoxin through the process of apoptosis.  

Verotoxin shows similar cytotoxicity on human glomerular microvascular endothelial cells via inflammatory mediators such as tumour necrosis factor-a, which induced an increase in the numbers of verotoxin receptors, leading to a microvascular thrombosis.  

Our patient was treated with antibiotics, plasma exchange, and continuous haemodialysis, with benefit.

During the course of the disease, our patient was in a delirious state with visual hallucinations and tonic convolution. She showed mild brain swelling on CT and diffuse slow waves in the frontal area on EEG, evidence of encephalopathy. Previous reports have shown that the incidence of encephalopathy in haemorrhagic-uraemic syndrome (mostly of VTEC infection) is 15%, including seizures in 17%–44%, altered consciousness in 7%–40%, and paralysis in 1%–16%. Many of the patients, including ours, seemed to have metabolic encephalopathy, but some developed encephalopathy without metabolic abnormalities.  

There is experimental evidence that verotoxin has direct virulence to both endothelial cells and neurons in the nervous system, and its initial lesion is in the hypothalamic areas, then given 250 mg/day diphenylhydantoin. During the next two weeks her kidney function, haemolytic anaemia, and encephalopathy gradually improved. 

After recovery of consciousness she began to complain of numbness of the limbs, manifesting in the legs. She described a tingling feeling like frost bite when she was lying on the bed, and this gradually exacerbated to be a burning pain. On examination she was alert and cooperative. Her cranial nerves were normal. Muscle strength was normal and coordination was intact. Deep tendon reflexes were decreased in the four limbs. Sensation for vibration was impaired in the lower legs, but preserved for pin prick, light touch, and joint positional sensation. Brain CT disclosed mild, unlar, and tibial nerves, and no evidence of conduction block. However, there were decrements of amplitudes of the sensory nerve action potentials (3.11 mV) and sural (0.98 mV) nerves. These findings and the clinical features confirmed the diagnosis of sensory dominant, axonal polyneuropathy. She was given 300 mg/day sulfameth (an anti-infective agent) and 1500 µg/day mecobalamin (vitamin B12) without effect. Two weeks after administration of 300 mg/day oral mecoxetine, her numbness and pain gradually disappeared.
spreading into the hippocampus and the brainstem. The convulsions in our patient were successfully treated with 250 mg/day diphenylhydantoin, and her encephalopathy gradually improved during plasma exchange and haemodialysis.

After recovering consciousness, she began to complain of numbness of her limbs, and a burning pain which exacerbated in the night. Nerve conduction studies and the clinical features confirmed the diagnosis of sensory-dominant, axonal polyneuropathy. At this stage metabolic abnormalities were not detected and serum concentrations of vitamins B1, B6, and B12 were normal. Her numbness and sensation ameliorated after 2 weeks administration of 300 mg/day oral mexiteline, an agent with a membrane stabilising effect. Up to now, to our knowledge, peripheral neuropathy has not been reported in VTEC infection other than in one patient, by Hamano et al., who showed bilateral phrenic nerve palsy for 2 weeks after recovering consciousness. The above experimental evidence suggests that microcirculatory disturbance or neurotoxicity to the neuronal cells by VTEC toxin could cause axonal neuropathy in VTEC infection.

RYUJI SAKAKIBARA
TAKAMICHI HATTORI
KEIKO MIZOBUCHI
SATOSHI KUWABARA
Department of Neurology
MITSUGU OGAWA
First Department of Internal Medicine, Chiba University, 1–8–1 Inohana Chou-ku, Chiba, 260, Japan.

Correspondence to: Dr Ryuji Sakakibara, Department of Neurology, Chiba University, 1–8–1 Inohana Chou-ku, Chiba, 260, Japan.

Crying spells as symptoms of a transient ischaemic attack

In the absence of depression, crying spells associated with neurological disease usually result from pseudobulbar palsy or, more rarely, from crying seizures. To our knowledge, there are no prior reports of crying spells heralding or signifying a transient ischaemic attack. We report on a patient with spells heralding or signifying a transient ischaemic attack. The patient did not complain of paraesthesias in the head or arm. He had no history of hypertension, diabetes mellitus, coronary artery disease, or an old myocardial infarction, raised cholesterol concentrations, or a history of heavy smoking.

Within 30 minutes of his initial crying spell, his headache had resolved but he became aware of numbness over his left face and numbness and pain in his left neck and arm. The numbness was not progressive, and the patient did not complain of paraesthesias in his trunk or limbs. He had photophobia, nausea or vomiting, blurred vision, visual obscurations, difficulty swallowing, dysarthria, or focal weakness. Over the next to 2 hours, he had five more crying spells, each lasting 5 to 10 minutes, occurring out of context, without precipitating factors or sadness, with an acute onset and offset, and without alteration of consciousness. The patient's left face and arm numbness persisted during and between the spells but abruptly resolved shortly after his last crying spell. This patient had hypertension, diabetes mellitus, coronary artery disease, an old myocardial infarction, raised cholesterol concentrations, and a history of heavy smoking.

On examination between recurrent crying spells, his blood pressure was 143/92 with a regular pulse of 62, and there were no carotid bruits. His mental status was normal. Cranial nerve examination showed normal extraocular movements. On the left nasolabial fold and decreased pinprick sensation over his left face through a brisk jaw jerk. The rest of the neurological examination showed mild weakness in his left upper arm and decreased pinprick and temperature sensation over the left half of his body. Reflexes were +2 and symmetric with downgoing toes. The patient lacked predisposing depression, depressive symptoms, or prior crying spells as an adult except for a single episode during dental anaesthesia. At the time of his admission, he had not had any recent adverse events in his life, and was totally surprised by his reaction.

The patient's crying spells, paraesthesias, and neurological findings entirely resolved within about 3 hours. Routine laboratory tests, ECG, and CT were normal. Two days after admission, MRI disclosed a mild degree of white matter atrophy over the right frontal horn and an ED Sagittal brain, with frontal intermittent rhythmic delta activity but no epileptiform changes. Carotid Doppler studies showed atherosclerotic changes without haemodynamically relevant obstruction. He was discharged on antipateleptoid therapy with aspirin.

Crying spells of patients with pseudobulbar palsy, and neurological findings entirely resolved within about 3 hours. Routine laboratory tests, ECG, and CT were normal. Two days after admission, MRI disclosed a mild degree of white matter atrophy over the right frontal horn and an ED Sagittal brain, with frontal intermittent rhythmic delta activity but no epileptiform changes. Carotid Doppler studies showed atherosclerotic changes without haemodynamically relevant obstruction. He was discharged on antipateleptoid therapy with aspirin.

Crying or dacrystic seizures also occur but are rare. These seizures are part of the range of complex partial seizures and usually emanate from the right temporolimbic system. Crying seizures may result from prior cerebral infarctions. Although our patient had mild mismatching of his left face, he had no evidence suggesting definite seizure activity. It is likely that this patient had a single transient ischaemic attack with multiple crying spells. The localisation of his attack is unclear; involvement of the right thalamus or neighbouring internal capsule is a possibility. Similar to spells of laughter, spells of crying may occur in relation to unilateral cerebrovascular events. Although most reports of crying after unilateral strokes have reported left hemispheric lesions, crying also may result from right hemispheric strokes. Even more similar to our patient, sudden laughing spells, "le fou rire prodromique,” rarely precede strokes involving the left capsular-thalamic, lenticular-caudate, or pontine regions. Our patient may have had a comparable phenomenon from the right hemisphere.

Crying spells may include dysarthria, cachexia, or apathetic changes, or may progress to a state of pseudobulbar palsy in patients with lesions of the right hemisphere. In patients with lesions of the right hemisphere, crying spells may be followed by a state of pseudobulbar palsy in patients with lesions of the right hemisphere. In patients with lesions of the right hemisphere, crying spells may be followed by a state of pseudobulbar palsy in patients with lesions of the right hemisphere. In patients with lesions of the right hemisphere, crying spells may be followed by a state of pseudobulbar palsy in patients with lesions of the right hemisphere.
Most patients with continuous drop type orthostatic hypotension reported reduced endurance for more than 10 minutes of exercise (easy fatigability). Two experienced syncope more than 20 minutes after standing.

We used a Swan-Ganz catheter to investigate the haemodynamics in three patients with orthostatic hypotension of the continuous drop type. To prevent the concentration of plasma, saline of calculated volume was infused during tilting. During the continuous decrease in blood pressure, cardiac output proportionally decreased but systemic vascular resistance did not change (figure).

Our results suggest that in many patients with MSA the blood pressure drops continuously on standing. The continuous blood pressure drop is caused by continuous reduction of cardiac output. A part of the mechanism for continuous reduction of cardiac output should be lack of reflex tachycardia and no significant release of noradrenaline during the decrease in blood pressure. A slight increase in packed cell volume (mean=1.4%) during the decrease in blood pressure. An account of respiratory aspects of neurological disease.

Respiratory aspects of neurological disease.

An account of respiratory aspects of neurological disease, such as the highly informative one presented, would be incomplete without mention of breathlessness resulting from neurogenic pulmonary oedema, characterised by an “increase in extravascular lung water in patients who have sustained a change in neurological condition”.

Neurological disorders associated with this syndrome include subarachnoid haemorrhage, middle cerebral artery stroke, and cerebellar haemorrhage. Brain stem stroke, acute hydrocephalus due to colloid cyst of the third ventricle, closed head injury, and status epilepticus, were also documented as risk factors in a literature review by Smith and Matthay, who proposed, on the basis of their own study, that increased pulmonary vascular hydrostatic pressure might be a more significant aetiopathogenic mechanism than increased pulmonary capillary permeability.

A more direct link between neurogenic myocardial damage and pulmonary oedema can be postulated when subarachnoid haemorrhage is complicated by reversible severe left ventricular dysfunction, as documented in two cases reported by Wells et al.

CORRESPONDENCE


With orthostatic hypotension of the continuous drop type, the final conclusion and its interpretation require further study.

We think that more than a 20 minute tilt up study is needed to evaluate orthostatic hypertension and that reduced endurance of exercise and the syncope that occurs some time after standing should be considered symptoms of a continuous drop in blood pressure.

TAKANORI YOKOTA
KAZUTO MITANI
YUKINOBU SAITO
Department of Neurology

TOSHIYUKI ONIKI
Third Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo 113, Japan

MICHYUKI HAYASHI
Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo 183, Japan

Correspondence to: Dr Takanori Yokota, Department of Neurology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Telephone +81-3-5803-5234; fax +81-3-5808-0169.


O M P JOLOBE
Department of Medicine for the Elderly, Tameside General Hospital, Fountain Street, Ashton under Lyne OL6 9RW, UK
Gastrointestinal symptoms are rare: rather in the late onset of gait ataxia, and can be identified by in- 1
creased antigliadin antibody titres in the presence of appropriate histocompatibility antigens. 
We agree with Hadjivassiliou et al, however, that gluten ataxia can be distinguished by the late onset of gait ataxia and the relatively mild upper limb signs. Our results support the finding of a late onset in these patients, but this feature cannot be consi- dered a distinctive one. In fact, in our popu- lation 11 out of 24 patients with idiopathic cerebellar ataxia had a late onset, but only three of them were affected by celiac disease. Furthermore, we do not think that celiac patients may be distinguished by mild upper limb sign and coexistent neuropathy; in our study 20 out of 24 patients with idiopathic cerebellar ataxia, including the three patients with celiac disease, had ataxic gait as the pres- enting and prominent clinical feature. Simi- larly, nerve conduction studies, performed in 17 out of 24 patients, showed a peripheral neuropathy in nine, including two out of the three patients with celiac disease. We understand that some discrepancies arise comparing our study with that of Hadji- vassiliou et al. Firstly, only six out of their 28 patients had evidence of cerebellar atrophy on MRI; whereas all of our patients had cer- ebellar atrophy. Secondly, many of their patients had a peripheral neuropathy in the absence of cerebellar atrophy. This finding could explain the relatively mild upper limb signs. Although two of our three celiac patients had a clinically silent peripheral neu- ropathy, we think that their ataxia was explained by cerebellar atrophy. Thirdly, we found a high prevalence (12.5%) of celiac disease on duodenal biopsy among patients with idiopathic cerebellar ataxia, whereas none of the six patients with cerebellar atrophy described by Hadjivassiliou et al showed histological features of celiac disease. It would be interesting to know the preva- lence of gluten ataxia among all ataxic patients screened for antigliadin by Hadjivassiliou et al. Our series is too small to estimate the sen- sitivity of both antigliadin and antianti- dymium antibodies in gluten ataxia; unfortu- nately Hadjivassiliou et al did not report any data on antianti antibodies screening in their patients. On the other hand, we were surprised at the high prevalence of antigliadin antibody positivity (12%) in the normal population studied by Hadjivassiliou et al in a previous report. This is by contrast with the 2% of antigliadin antibody positivity found in a large population by Catassi et al. Further studies are required to better characterise the syndrome of cerebellar ataxia associated with celiac disease or gluten sensitivity.

M HADJIVASSILIOU R A GRÜNEWALD G A B DAVIES-JONES
Department of Neurology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
Correspondence to: Dr G A B Davies-Jones, Department of Neurology, Royal Hallamshire Hos- pital, Glossop Road, Sheffield S10 2JF, UK.


Pellecchia et al reply:
We thank Hadjivassiliou et al for their interesting comments on our paper. They suggest that patients with gluten ataxia can be distinguished by the late onset of gait ataxia and the relatively mild upper limb signs. Our results support the finding of a late onset in these patients, but this feature cannot be considered a distinctive one. In fact, in our population 11 out of 24 patients with idiopathic cerebellar ataxia had a late onset, but only three of them were affected by celiac disease. Furthermore, we do not think that celiac patients may be distinguished by mild upper limb signs and coexistent neuropathy; in our study 20 out of 24 patients with idiopathic cerebellar ataxia, including the three patients with celiac disease, had ataxic gait as the presenting and prominent clinical feature. Similarly, nerve conduction studies, performed in 17 out of 24 patients, showed a peripheral neuropathy in nine, including two out of the three patients with celiac disease. We understand that some discrepancies arise comparing our study with that of Hadjivassiliou et al. Firstly, only six out of their 28 patients had evidence of cerebellar atrophy on MRI; whereas all of our patients had cerebellar atrophy. Secondly, many of their patients had a peripheral neuropathy in the absence of cerebellar atrophy. This finding could explain the relatively mild upper limb signs. Although two of our three celiac patients had a clinically silent peripheral neuropathy, we think that their ataxia was explained by cerebellar atrophy. Thirdly, we found a high prevalence (12.5%) of celiac disease on duodenal biopsy among patients with idiopathic cerebellar ataxia, whereas none of the six patients with cerebellar atrophy described by Hadjivassiliou et al showed histological features of celiac disease. It would be interesting to know the prevalence of gluten ataxia among all ataxic patients screened for antigliadin by Hadjivassiliou et al. Our series is too small to estimate the sensitivity of both antigliadin and antiantidymium antibodies in gluten ataxia; unfortunately Hadjivassiliou et al did not report any data on antianti antibodies screening in their patients. On the other hand, we were surprised at the high prevalence of antigliadin antibody positivity (12%) in the normal population studied by Hadjivassiliou et al in a previous report. This is by contrast with the 2% of antigliadin antibody positivity found in a large population by Catassi et al. Further studies are required to better characterise the syndrome of cerebellar ataxia associated with celiac disease or gluten sensitivity.

M PELLECHIA R SCALA A FILLA G DE MICHELE P BARONE
Department of Neurological Sciences, Via S Pansini 5, 80131 Naples, Italy

the EMG pattern in patients with myotonic dystrophy show a multitude of deflexions including expression of myotonia, myopathy, muscular atrophy, and neural abnormalities. ¹, ²

The possible management of myotonia and some of its clinical manifestations, such as myoclonus,¹ by means of myotonic drugs (disopyramide and procainamide), justifies the use of the same pharmacological approach in anal sphincter dysfunction manifested in a few cases of myotonic dystrophy.

We conclude that treatment of faecal incontinence with procainamide should always be attempted before any surgical option in patients with myotonic dystrophy.

G PELLICCIIONI
O SCARPINO
Department of Neurology, INRCA, Geriatric Hospital, Ancona, Italy

V PILONI
Department of Radiology, Ac. N 7, Ancona, Italy

Correspondence to: Dr Giuseppe Pelliccionii, Department of Neurology, Geriatric Hospital, via della Magnanapoli 6, 60139 Ancona, Italy. Telephone 0039 071 8003432; fax 0039 071 8003530; email: o.scarpino@fastnet.it


Flail arm syndrome or Vulpian-Bernhardt's form of amyotrophic lateral sclerosis

We read with interest the article by Hu et al concerning flail arm syndrome, a distinctive variant of amyotrophic lateral sclerosis. The authors presented a subgroup of patients affected by amyotrophic lateral sclerosis that predominately showed signs of lower motor neuron involvement. The comparative study with the rest of the amyotrophic lateral sclerosis group supplies very interesting information in this respect. However, in the 1960s, in the differential diagnosis of this syndrome, it was observed that the muscles predominantly affected in Vulpian-Bernhardt's form were the deltoideus, the infraespinatus, the supraespinatus, the sternocleidomastoideus, and the teres minor. The prominence of weakness in these muscles permitted its distinction from that previously called Erb's dystrophy.¹

As a consequence of the atrophy of these muscles, the upper limbs show a characteristic pattern, with the shoulders slumped, and the arms, forearms, and hands in pronation. As the illness progresses, the hand muscles are affected, with atrophy of the following muscles: opponens pollicis, flexor brevis pollicis, abductor pollicis brevis, adductor pollicis brevis, adductor pollicis longus, interossii, and lumbricales, which leads to the formation of the characteristic Aran-Duchenne hand.

Obviously, signs of corticospinal involvement with hyperreflexia in the lower limbs and Babinski's sign both appear. In the initial stages of the illness, there is no effect on the diaphragm. The presence of signs of involvement of the upper motor neuron, its different clinical evolution, and the data supplied by genetic molecular investigation allow us to distinguish the syndrome previously known as Vulpian-Bernhardt's rebaptised as flail arm syndrome from other motor neuron syndromes such as the spinal muscular atrophies, Kennedy's disease, multifocal motor neuropathy, and monomelic amyotrophy.

JOSEP GAMEZ
CARLOS CERVERA
AGUSTIN CODINA
Servicio de Neurologia, Hospital Universitari Vall d'Hebron, Passeig Vall d' Hebron 119–135, 08035 Barcelona, Spain

Correspondence to: Dr Josep Gamez, Servicio de Neurologia, Hospital Universitari Vall d' Hebron, Passeig Vall d' Hebron 119–135, 08035 Barcelona, Spain. Email: 17847@vcm.barcelona.caremail

Pain after whiplash

This latest study from Lithuania is an answer to many questions—namely, that the previous difficulties that these researchers had with identifying the late whiplash syndrome in Lithuania is that they were not looking “in the right place”. As it turns out, the problem is that Lithuanians simply are not behaving the way many in Western countries would like. There are some methodological issues which can be considered as, below, but the lesson of discarding “unsightly” data because it is too disturbing to one’s personal view and vested interest in the study which has already been taught elsewhere. Suffice it to say that the truth has been laid bare and we (those of us struggling with epidemic proportions of the late whiplash syndrome in our own countries) now need to enlighten ourselves and put this data to practical use in helping whiplash patients rather than resisting the inevitable.

After completion of the first historical cohort study, this more recent study selects an entirely separate, distinct sample of these “misbehaving” Lithuanians, but in a more intriguing fashion. This is the first inception cohort study with people who have not been preselected by their attendance at emergency departments, or contaminated by therapists or lawyers, can be studied to appreciate the natural evolution of the injury which underlies whiplash associated disorders grades 1 and 2. This is the study’s greatest strength. The study has, however, its limitations.

The first consideration is that there were 98 accident victims who reported acute symptoms, and thus were at risk for the late whiplash syndrome. How does this compare with other studies documenting the natural evolution of the late whiplash syndrome?

The Swiss study may be useful for comparison because it too has only 117 subjects, yet is much quoted. Setting aside for the moment that the Swiss study is hampered by the selection strategy of advertising for subjects, and has a host of other reportedly fatal faults¹, and giving some benefit of the doubt, the study is said to be an accurate representation of the state of affairs in Switzerland at that time, in 1996. Obviously, signs of involvement of the upper motor neuron, its different clinical evolution, and the data supplied by genetic molecular investigation allow us to distinguish the syndrome previously known as Vulpian-Bernhardt's rebaptised as flail arm syndrome from other motor neuron syndromes such as the spinal muscular atrophies, Kennedy's disease, multifocal motor neuropathy, and monomelic amyotrophy.
A second consideration is that perhaps these Lithuanians are in very minor collisions. True, some of their vehicles were completely wrecked, but perhaps the vehicles were not very good quality and so were easily damaged. Perhaps that is why this cohort had such a good outcome and only minor injuries. This is an unhelpful consideration however, as studies in Canada have shown that those with absolutely no vehicle damage, in very low velocity collisions, are just as likely to report whiplash pain as those in more severe collisions. Lithuanians seem to behave appropriately then for minor collisions (if that is what they indeed had), but Canadians seem unable to behave appropriately. Again, another cultural difference in the rate of recovery from whiplash injury is demonstrated.

Thirdly, there are sex differences and even differences in seat belt usage between this population and some others, but even then, it does not necessarily matter what sex, age, and use of seat belts there is in other western countries, none of these preclude chronic pain. In Lithuania, those who were female, and who did not wear seat belts, still insisted on behaving as the rest of the cohort. Finally, perhaps the Lithuanians simply refuse to report their chronic pain, and chronic pain cannot be studied in other countries in this way. The Lithuanian's lack of reluctance to report acute pain, but perhaps for some reason wish to “suffer in silence” in spite of chronic pain and disability. This would be a potential flaw if it was not simultaneously shown in this study that the general Lithuanian population reports the same prevalence, frequency, and character of neck pain and headache as does the general population in western countries. If there were studies on barriers to identifying symptoms, the control population would have grossly underreported their symptoms. Indeed, chronic pain can and is reported by studies in many different cultures and languages, including Japan, France, Italy, and others. If researchers in these non-English speaking populations can use simple questionnaires to document the late whiplash syndrome so effectively there, then the same should be possible in Lithuania.

And so, despite the potential limitations of this study as outlined, there is no way to get around the stark realisation that the natural history of acute whiplash injury in Lithuania is a benign syndrome with 4 weeks or less of pain. Equally compelling is the fact that Lithuania is not the only place where researchers are having difficulty identifying epidemics of chronic pain. Recovery from acute whiplash injury without neurological injury or fracture routinely occurs within 4–6 weeks in Germany and Greece. The time is now right for a reconciliation of these epidemiological observations with our own experience of late whiplash syndrome in western countries. The truth has been laid bare and it is our responsibility to utilise this truth to help prevent the chronic pain and the suffering we otherwise encounter.

BOOK REVIEWS


This book purports itself to be a comprehensive reference. Certainly the title would suggest so. However, it is clear that this is not a comprehensive text, but a book that is an update on particular timely topics in the field of pain medicine. There are sections on pain mechanisms in each chapter on the pharmacology of acute and chronic pain, and other chapters on postoperative pain, obstetric pain, and acute paediatric pain. There are three further chapters specifically on the management of chronic low back pain, cancer pain, and an overview of interventional pain techniques.

Many of the authors are internationally known and this is partly the book’s strongest point—one does get a state of the art review and to this end I warmly welcome this book as an addition to the bookshelf to update a busy anaesthetist or pain specialist, though the chapter on chronic low back pain and cancer pain will also be of interest to those in other fields.

The chapter on the anatomy and physiology of pain is excellent in that it has clear explanations and a number of very helpful diagrams. Unfortunately it fails to mention increasing understanding of the role of GABA in mediating analgesia within the spinal cord and furthermore does not mention some of the other endogenous changes which are well known to occur in chronic pain states such as central sprouting and peripheral switching.

The chapter on pharmacology of acute and chronic pain is well written, but unfortunately a lot of time is spent on non-steroidal drugs. There is a review of the adjuvant drugs such as gabapentins and anticonvulsants that are used in chronic pain, however one is left at the end with a sense of knowing about the drugs but not quite to use them. There is no mention of the increasing use of gabapentin nor of other drugs that are some- times used in chronic pain states such as clonidine and other sympathetic agents or calcium channel blockers.

The chapter on acute postoperative pain management is well written and informative as are the chapters on obstetric and paediatric pain. The chapter on chronic low back pain by Rauck is one of the best I have seen for some time. It is a comprehensive review of both acute and chronic low back pain. It is excellent as it also mentions treatments that are often performed outside the medical special- istic arena. I was pleased to see in it the mention of some of the newly evolving techniques such as facet denervations, spinal cord stimulation, and disc denervation. It was a pity that the randomised control trials which have shown facet denervation to be an outstandingly useful technique for chronic back pain were not mentioned. It was also a pity that the reference to the disc denervation procedure was to another text book rather than any original papers.

The chapter on cancer pain management has been written by internationally known authors and is an excellent summary of the subject. In the section on interventional pain techniques the emphasis was on spinal cord stimulation, radiofrequency, and cryoneu- rolysis. Again this chapter has been written by an internationally well known author who concentrated on general overview of the techniques rather than a how to do it approach, which I feel will only be useful to a bigger text for. In summary I think that this volume would make an excellent addition to the bookshelf of those involved in the treatment and management of pain.

RAJESH MUNGLANI


This is a really excellent book which is both comprehensive and amazingly up to date, with the inclusion of many references from as late as 1997.

As a clinical neurologist and neuropsy- chologist with a longstanding interest in the dementias, I found it extremely valuable. The editor has done a very good job in posing a coherence, format, and style, which is often lacking from multic contributor textbooks.

The title of the book is perhaps a little misleading in that the book includes, as well as traditional neuropathology, a very comprehensive overview of the molecular biology and genetics of the dementias. As would be expected, a considerable proportion of the book is dedicated to Alzheimer’s disease with chapters on both the clinical features, genetics, and the neuropathology. The frontotem- poral dementias are also well covered and the book includes a chapter on the developments related to chromosome 17 linked dementias. There are also sections on progres- sive supranuclear palsy, Huntington’s disease, corticobasal degeneration, dementia with lewy bodies, and prion diseases and vas- cular dementia.

The editor has managed to persuade many of the world’s experts to contribute. For instance, the chapter on prion diseases is by D’Almond and the recent Nobel laureate Prusiner, and the frontotemporal dementias are reviewed by Brun and Gustafson. Genet- ics of Alzheimer’s disease are dealt with by St George-Hyslop and the neuropathology of Alzheimer’s disease by Price and coworkers.
The standard of illustrations is excellent and the style generally very readable. I shall certainly find it extremely useful as a work of reference and for teaching purposes. The editor is to be complimented on producing such a delightful work.

JOHN HODGES


I very much enjoyed reviewing this textbook of instrumented spinal surgery written by Giuseppe Tabasso under the auspices of Jürgen Harms. Dr Harms is well known to all spinal surgeons and has made a very important contribution to the development of spinal surgery over the past 20 years, based on strong personal convictions. Many surgeons who manage spinal disorders would not choose to implement all of Professor Harms’ solutions but all who have a serious interest in the surgical treatment of the spine admire and are grateful for his contribution. Within this book spinal surgeons will find a rational and practical approach which will allow them to treat a wide range of spinal disorders according to well thought out principles.

The opening chapter describes spinal biomechanics under normal and pathological circumstances mainly by using easily understood drawings and diagrams. Some of these drawings reminded me of images that I have recently seen on an interactive CD ROM that I bought for my 4 year old son. This is not a criticism and I fully support any attempt to simplify the science of biomechanics which is often cloaked in seemingly contradictory jargon. Most spinal surgeons will be able to assimilate the two basic principles which underpin much of instrumented spinal surgery—namely, that the anterior column resists load compression forces and that the posterior column acts as a tension band which when disrupted should be reconstructed in compression. The remaining chapters cover fracture management, late kyphosis, metastatic tumours, spondylolisthesis, degenerative spinal disease, and infection. Each chapter sets out the principles of management which are illustrated schematically. There then follow case studies illustrated by radiological images including CT and MRI. These have reproduced well and surgeons will admire the technical precision and excellent anatomical reductions illustrated by these clinical cases. It is, however, a source of constant annoyance to spinal surgeons that perfect postoperative films do not always correlate with good clinical results and this discrepancy remains a source of fascination and mystery.

It is in the degenerative spine that this discrepancy between radiological and clinical findings is most apparent and it is partly for this reason that the management of these conditions is often controversial. It is difficult to disagree with much of the logic presented by the authors in planning their interventions but there is a danger that inexperienced surgeons may be misled into adopting complex solutions when often more simple operations will suffice. The authors' description of their approach to failed back surgery syndrome illustrates this problem and the inadequacies of attempting to treat a complex clinical problem by focusing on one aspect of it.

This book will be a useful addition to the shelves of spinal surgery textbooks and many orthopaedic and neurosurgical departmental libraries will wish to buy a copy.

RODNEY LAING


I wondered, when I received this book, how I could possibly say anything adverse about a book written by three such world renowned experts. I have heard them all lecture often and have seen them all at work. They have a vast knowledge and experience of treating disorders of peripheral nerves. In clinic and the operating theatre, they have shown myself and many trainees a clarity in their planning of management of complex problems that undermines one’s own thoughts. That clarity has continued in this text book of over 500 pages. The field of peripheral nerve surgery is covered comprehensively, commencing with descriptions of anatomy, physiology, and pathological reaction to injury. This is followed in subsequent chapters with descriptions of approaches to virtually all the main peripheral nerves, and the operative management of brachial plexus injury and outcomes is covered in three detailed chapters. These are followed by chapters on nerve entrapment, neuropathy, iatropathic injury, and neoplasm within the peripheral nerve. The final section covers electrodiagnosis, pain, nerve recovery, reconstruction techniques, and rehabilitation.

The text is well written, easy to read, and supplemented by some excellent line drawings similar to those used in Lundborg’s text. There are detailed plates showing histology and various imaging techniques. Each chapter is comprehensive, containing important historical aspects as well as up to date techniques, and there is an extensive reference section. I would recommend that trainees of all specialties dealing with peripheral nerve injuries should read much of this text and it would be extremely useful as a regular reference. It would also make an important and necessary addition to most medical libraries. All clinicians would be well advised to read the chapters on iatropathic injuries, not only for the extensive causes of such injuries encompassing all medical and surgical departments, but also for the précis of the changes occurring in medical negligence claims. This text represents good value for money.

IAN WHITWORTH